Guggenheim analyst Debjit Chattopadhyay maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $450.00. The company’s shares opened today at $394.19.
Chattopadhyay covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Voyager Therapeutics, and Intellia Therapeutics. According to TipRanks, Chattopadhyay has an average return of 12.1% and a 44.58% success rate on recommended stocks.
In addition to Guggenheim, Vertex Pharmaceuticals also received a Buy from UBS’s Colin Bristow in a report issued yesterday. However, on April 11, Robert W. Baird maintained a Sell rating on Vertex Pharmaceuticals (NASDAQ: VRTX).
The company has a one-year high of $448.40 and a one-year low of $316.43. Currently, Vertex Pharmaceuticals has an average volume of 1.24M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vertex Pharmaceuticals (VRTX) Company Description:
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
Read More on VRTX:
- Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study
- Biotech Alert: Searches spiking for these stocks today
- Alpine Immune Sciences downgraded to Market Perform from Outperform at Leerink
- Analyst thinks this drugmaker could be next after Alpine’s $4.9B acquisition
- DoorDash upgraded, Airbnb downgraded: Wall Street’s top analyst calls
